Literature DB >> 31576362

Breakthroughs and challenges in the management of tropomyosin receptor kinase fusion-positive tumors.

Hirva Mamdani1, Shadia I Jalal2.   

Abstract

Entities:  

Year:  2019        PMID: 31576362      PMCID: PMC6685873          DOI: 10.21037/atm.2019.06.41

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN: 2305-5839


× No keyword cloud information.
  10 in total

Review 1.  Trk receptor tyrosine kinases: a bridge between cancer and neural development.

Authors:  A Nakagawara
Journal:  Cancer Lett       Date:  2001-08-28       Impact factor: 8.679

2.  Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).

Authors:  Alexander Drilon; Salvatore Siena; Sai-Hong Ignatius Ou; Manish Patel; Myung Ju Ahn; Jeeyun Lee; Todd M Bauer; Anna F Farago; Jennifer J Wheler; Stephen V Liu; Robert Doebele; Laura Giannetta; Giulio Cerea; Giovanna Marrapese; Michele Schirru; Alessio Amatu; Katia Bencardino; Laura Palmeri; Andrea Sartore-Bianchi; Angelo Vanzulli; Sara Cresta; Silvia Damian; Matteo Duca; Elena Ardini; Gang Li; Jason Christiansen; Karey Kowalski; Ann D Johnson; Rupal Patel; David Luo; Edna Chow-Maneval; Zachary Hornby; Pratik S Multani; Alice T Shaw; Filippo G De Braud
Journal:  Cancer Discov       Date:  2017-02-09       Impact factor: 39.397

3.  A human oncogene formed by the fusion of truncated tropomyosin and protein tyrosine kinase sequences.

Authors:  D Martin-Zanca; S H Hughes; M Barbacid
Journal:  Nature       Date:  1986 Feb 27-Mar 5       Impact factor: 49.962

Review 4.  TrkB inhibition as a therapeutic target for CNS-related disorders.

Authors:  Fabien Boulle; Gunter Kenis; Maxime Cazorla; Michel Hamon; Harry W M Steinbusch; Laurence Lanfumey; Daniel L A van den Hove
Journal:  Prog Neurobiol       Date:  2012-06-13       Impact factor: 11.685

5.  Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.

Authors:  Alexander Drilon; Theodore W Laetsch; Shivaani Kummar; Steven G DuBois; Ulrik N Lassen; George D Demetri; Michael Nathenson; Robert C Doebele; Anna F Farago; Alberto S Pappo; Brian Turpin; Afshin Dowlati; Marcia S Brose; Leo Mascarenhas; Noah Federman; Jordan Berlin; Wafik S El-Deiry; Christina Baik; John Deeken; Valentina Boni; Ramamoorthy Nagasubramanian; Matthew Taylor; Erin R Rudzinski; Funda Meric-Bernstam; Davendra P S Sohal; Patrick C Ma; Luis E Raez; Jaclyn F Hechtman; Ryma Benayed; Marc Ladanyi; Brian B Tuch; Kevin Ebata; Scott Cruickshank; Nora C Ku; Michael C Cox; Douglas S Hawkins; David S Hong; David M Hyman
Journal:  N Engl J Med       Date:  2018-02-22       Impact factor: 91.245

Review 6.  TRKing down an old oncogene in a new era of targeted therapy.

Authors:  Aria Vaishnavi; Anh T Le; Robert C Doebele
Journal:  Cancer Discov       Date:  2014-12-19       Impact factor: 39.397

Review 7.  NTRK gene fusions as novel targets of cancer therapy across multiple tumour types.

Authors:  Alessio Amatu; Andrea Sartore-Bianchi; Salvatore Siena
Journal:  ESMO Open       Date:  2016-03-18

Review 8.  Entrectinib: an orally available, selective tyrosine kinase inhibitor for the treatment of NTRK, ROS1, and ALK fusion-positive solid tumors.

Authors:  Dazhi Liu; Michael Offin; Stephen Harnicar; Bob T Li; Alexander Drilon
Journal:  Ther Clin Risk Manag       Date:  2018-07-20       Impact factor: 2.423

9.  Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.

Authors:  Jean-Charles Soria; Yuichiro Ohe; Johan Vansteenkiste; Thanyanan Reungwetwattana; Busyamas Chewaskulyong; Ki Hyeong Lee; Arunee Dechaphunkul; Fumio Imamura; Naoyuki Nogami; Takayasu Kurata; Isamu Okamoto; Caicun Zhou; Byoung Chul Cho; Ying Cheng; Eun Kyung Cho; Pei Jye Voon; David Planchard; Wu-Chou Su; Jhanelle E Gray; Siow-Ming Lee; Rachel Hodge; Marcelo Marotti; Yuri Rukazenkov; Suresh S Ramalingam
Journal:  N Engl J Med       Date:  2017-11-18       Impact factor: 91.245

10.  The landscape of kinase fusions in cancer.

Authors:  Nicolas Stransky; Ethan Cerami; Stefanie Schalm; Joseph L Kim; Christoph Lengauer
Journal:  Nat Commun       Date:  2014-09-10       Impact factor: 14.919

  10 in total
  1 in total

1.  PROTAC Compounds Targeting TRK for Use in Cancer Therapeutics.

Authors:  Robert B Kargbo
Journal:  ACS Med Chem Lett       Date:  2020-05-18       Impact factor: 4.345

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.